



Transmucosis publication chosen in top 25 COVID-19 articles in Nature Communications

- ***Strong research community endorsement for Transmucosis' intranasal vaccines***

College Park MD, USA, 7 March 2024 – Transmucosis LLC (“Transmucosis” or the “Company”), a private biotechnology company pioneering a novel intranasal vaccine platform, today announces that the article "An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission" was one of the most read *Nature Communications* articles in COVID-19 in 2023.

Nature Communications published more than 8,500 articles in 2023. The top ranking of the paper by our Principle Investigator and CSO Prof. Dr. Xiaoping Zhu on our intranasal vaccine against COVID-19 is a significant achievement and demonstrates our valuable contribution to vaccine research.

-ENDS-

For more information, please contact:

Transmucosis LLC

Herbert Heyneker, CEO

hheyneker@transmucosis.com

About Transmucosis

Transmucosis is a developer of protein-based intranasal vaccines against respiratory diseases. It leverages the unique properties of the FcRn receptor to facilitate the passage of nasal vaccines across the mucosal surface. Transmucosis developed multiple influenza vaccines. Furthermore, the company obtained preclinical proof of concept with intranasal vaccines against all tested strains of coronavirus, and against RSV. Transmucosis LLC was founded by Dr. Herbert Heyneker (CEO) and Prof. Dr. Xiaoping Zhu (CSO). Transmucosis signed an exclusive license agreement with the University of Maryland covering all research on the intranasal vaccine platform by the lab of Prof. Zhu's. The lab has been funded for more than a decade by NIH and other grants. The company is located at 8075 Greenmead Drive, College Park, Maryland 20742-3711, USA.